 |
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk assessments. The established platform provides in vitro high-throughput screening within this NAM framework, empowering researchers in diverse sectors with faster and cost-effective tools to assess chemical-related risk to human health.
The SAFETYscan47 functional panel comprises 47 human-relevant targets pivotal in the assessment of clinical adverse drug reactions (ADRs), supporting all pharmaceutical drug discovery stages and aligning early safety evaluations with clinical predictions, in addition to supporting other research domains such as food, cosmetics, and industrial chemicals. A recent case study published in the Society of Toxicology showcases its utility with in vitro risk assessment.
This SAFETYscan47 recognition offers solutions to challenges posed by traditional in vivo risk assessments. Beyond ethical concerns, they fail to fully replicate human in vivo mechanistic-related adverse events. Human genetic diversity is rarely considered, leading to uncertainties in translating results to human populations. Eurofins Discovery's platform addresses these issues by delivering human-relevant, functional data with higher throughput and at lower costs.
Developed in alignment with the European Commission's chemicals strategy, U.S. EPA's Chemical Safety for Sustainability Strategic Research Action Plan, and other global strategies, SAFETYscan47 echoes the international drive for chemical-risk mitigation.
By integrating in vitro to in vivo extrapolation (QIVIVE) and leveraging mechanism-based methods, this Eurofins Discovery technology supports global efforts to ensure a toxic-free environment and safe therapeutic development. With its focus on efficiency and accuracy, SAFETYscan47 is a breakthrough in modern chemical safety evaluation.
About Eurofins Discovery
Eurofins Discovery is recognized as the industry leader for providing drug discovery researchers with the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, Eurofins Discovery also offers a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. Eurofins Discovery supports a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins and enzymes. Eurofins Discovery's capabilities, expertise, knowledge and skill sets allow clients to work with a single outsourcing provider (CRO) for all their drug discovery programs. Eurofins Discovery is part of the international network of Eurofins laboratories.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 62,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.